Avinger Inc Files Pre-14A Form with SEC
Avinger Inc (0001506928) has recently filed a PRE 14A form with the Securities and Exchange Commission, indicating an upcoming proxy statement relating to an annual meeting of shareholders. This filing is significant as it provides shareholders with essential information about matters that will be voted on at the meeting, such as the election of directors, executive compensation, and any other proposals put forth by the company.
Avinger Inc is a medical device company that specializes in the development and commercialization of image-guided, catheter-based systems for the treatment of patients with peripheral artery disease. The company’s innovative products aim to improve the diagnosis and treatment of vascular diseases, ultimately enhancing patient outcomes. For more information about Avinger Inc, please visit their website at https://www.avinger.com.
The PRE 14A filing by Avinger Inc provides shareholders with crucial information ahead of the annual meeting, allowing them to make informed decisions about company matters. Shareholders are encouraged to review the proxy statement carefully and participate in the voting process to have their voices heard on important issues impacting the company.
Read More:
Avinger Inc Submits Pre 14A SEC Filing: What You Need to Know
